Oxytocin-Augmented and Non-Sedating High-Intensity-Focused Ultrasound (HIFU) for Uterine Fibroids Showed Promising Outcome As Compared To HIFU Alone or Uterine Artery Embolization.

Yu SC, Cheung EC, Leung VY, Fung LW

Ultrasound in medicine & biology4 Sept 2019Cited by 12 (Europe PMC)

PMID31493956DOI10.1016/j.ultrasmedbio.2019.07.410PepBankPUB-31493956

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone7

In this study, Oxytocin was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Oxytocin.

01HumanNot a test of Oxytocin aloneObservational studyEfficacy outcome
In patients with uterine fibroids, all patients in the oxytocin-augmented modified HIFU group were symptom free at 6 months, significantly better than both control groups.
In plain wordsIn women with uterine fibroids, all patients given the new oxytocin HIFU protocol were symptom free at 6 months, more than in both comparison groups.
Peptide
Oxytocin
Outcome
IncreaseSymptom-free patients at 6 months
Study
n = 60
Comparator
HIFU alone and uterine artery embolization
Outcome group
Uterine fibroid outcomes · Reproductive and sexual health
Measurements
Symptom free
100%
study group
Source sentences
Summary
At 6 mo, all patients in the study group became symptom free (9/9, 100%), a result significantly better than that of both control groups.
1 context sentence(design, population, supporting numbers)
Summary · context
The treatment outcomes of 9 consecutive patients (study group) were compared with those of 51 patients (control group) who had been randomized (1:1) to receive HIFU (n = 24) or uterine artery embolization ([UAE] n = 27).
In this study, Oxytocin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Oxytocin.
Report a problemFND-3149395604
02HumanNot a test of Oxytocin aloneObservational studyEfficacy outcome
In patients with uterine fibroids, the oxytocin-augmented modified HIFU protocol gave a smaller median fibroid volume proportion at 3 months than uterine artery embolization.
In plain wordsIn women with uterine fibroids, fibroids shrank more at 3 months with the new oxytocin HIFU protocol than with uterine artery embolization.
Peptide
Oxytocin
Outcome
DecreaseFibroid volume at 3 months versus uterine artery embolization
Study
n = 36
Comparator
Uterine artery embolization
Outcome group
Uterine fibroid outcomes · Reproductive and sexual health
Measurements
Median fibroid volume proportion
51.1%
study group
Median fibroid volume proportion
66.2%
UAE
Source sentences
Summary
At 3 mo, the median proportion of fibroid volume compared with the baseline was 51.1% in the study group, significantly smaller than that in the control groups (HIFU 76.6%, UAE 66.2%).
1 context sentence(design, population, supporting numbers)
Summary · context
The treatment outcomes of 9 consecutive patients (study group) were compared with those of 51 patients (control group) who had been randomized (1:1) to receive HIFU (n = 24) or uterine artery embolization ([UAE] n = 27).
In this study, Oxytocin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Oxytocin.
Report a problemFND-3149395603
03HumanNot a test of Oxytocin aloneObservational studyEfficacy outcome
In patients with uterine fibroids, a higher proportion had good quality of life with the oxytocin-augmented modified HIFU protocol than with uterine artery embolization.
In plain wordsIn women with uterine fibroids, more patients had good quality of life with the new oxytocin HIFU protocol than with uterine artery embolization.
Peptide
Oxytocin
Outcome
IncreaseGood quality of life versus uterine artery embolization
Study
n = 34
Comparator
Uterine artery embolization
Outcome group
Uterine fibroid outcomes · Reproductive and sexual health
Measurements
Good quality of life
71.4%
study group
Good quality of life
25.9%
UAE
Source sentences
Summary
The proportion of patients with good quality of life was significantly higher in the study group (5/7, 71.4%) compared with the control groups (HIFU 3/24, 12.5%; UAE 7/27, 25.9%).
1 context sentence(design, population, supporting numbers)
Summary · context
The treatment outcomes of 9 consecutive patients (study group) were compared with those of 51 patients (control group) who had been randomized (1:1) to receive HIFU (n = 24) or uterine artery embolization ([UAE] n = 27).
In this study, Oxytocin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Oxytocin.
Report a problemFND-3149395606
04HumanNot a test of Oxytocin aloneObservational studyEfficacy outcome
In patients with uterine fibroids, the oxytocin-augmented modified HIFU protocol gave a smaller median fibroid volume proportion at 3 months than HIFU alone.
In plain wordsIn women with uterine fibroids, fibroids shrank more at 3 months with the new oxytocin HIFU protocol than with HIFU alone.
Peptide
Oxytocin
Outcome
DecreaseFibroid volume at 3 months versus HIFU alone
Study
n = 33
Comparator
HIFU alone
Outcome group
Uterine fibroid outcomes · Reproductive and sexual health
Measurements
Median fibroid volume proportion
51.1%
study group
Median fibroid volume proportion
76.6%
HIFU
Source sentences
Summary
At 3 mo, the median proportion of fibroid volume compared with the baseline was 51.1% in the study group, significantly smaller than that in the control groups (HIFU 76.6%, UAE 66.2%).
1 context sentence(design, population, supporting numbers)
Summary · context
The treatment outcomes of 9 consecutive patients (study group) were compared with those of 51 patients (control group) who had been randomized (1:1) to receive HIFU (n = 24) or uterine artery embolization ([UAE] n = 27).
In this study, Oxytocin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Oxytocin.
Report a problemFND-3149395602
05HumanNot a test of Oxytocin aloneObservational studyEfficacy outcome
In patients with uterine fibroids, none in the oxytocin-augmented modified HIFU group needed re-intervention within 24 months, significantly better than the control HIFU group.
In plain wordsIn women with uterine fibroids, none treated with the new oxytocin HIFU protocol needed another procedure within 24 months, unlike many treated with HIFU alone.
Peptide
Oxytocin
Outcome
DecreaseRe-intervention within 24 months versus HIFU alone
Study
n = 33
Comparator
HIFU alone
Outcome group
Uterine fibroid outcomes · Reproductive and sexual health
Measurements
Re-intervention
62.5%
control HIFU group
Source sentences
Summary
Within 24 mo, none of the patients in the study HIFU group required re-intervention, a result significantly better than that in the control HIFU group (15/24, 62.5%).
1 context sentence(design, population, supporting numbers)
Summary · context
The treatment outcomes of 9 consecutive patients (study group) were compared with those of 51 patients (control group) who had been randomized (1:1) to receive HIFU (n = 24) or uterine artery embolization ([UAE] n = 27).
In this study, Oxytocin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Oxytocin.
Report a problemFND-3149395607
06HumanNot a test of Oxytocin aloneObservational studyEfficacy outcome
In patients with uterine fibroids, a higher proportion had good quality of life with the oxytocin-augmented modified HIFU protocol than with HIFU alone.
In plain wordsIn women with uterine fibroids, more patients had good quality of life with the new oxytocin HIFU protocol than with HIFU alone.
Peptide
Oxytocin
Outcome
IncreaseGood quality of life versus HIFU alone
Study
n = 31
Comparator
HIFU alone
Outcome group
Uterine fibroid outcomes · Reproductive and sexual health
Measurements
Good quality of life
71.4%
study group
Good quality of life
12.5%
HIFU
Source sentences
Summary
The proportion of patients with good quality of life was significantly higher in the study group (5/7, 71.4%) compared with the control groups (HIFU 3/24, 12.5%; UAE 7/27, 25.9%).
1 context sentence(design, population, supporting numbers)
Summary · context
The treatment outcomes of 9 consecutive patients (study group) were compared with those of 51 patients (control group) who had been randomized (1:1) to receive HIFU (n = 24) or uterine artery embolization ([UAE] n = 27).
In this study, Oxytocin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Oxytocin.
Report a problemFND-3149395605
07HumanNot a test of Oxytocin aloneObservational studySafety outcome
In patients with uterine fibroids, oxytocin-augmented non-sedating HIFU with a modified protocol had no major adverse event.
In plain wordsIn women with uterine fibroids, a new HIFU treatment protocol that included oxytocin had no major adverse event.
Peptide
Oxytocin
Outcome
No significant changeMajor adverse events
Study
n: not reported in source
Outcome group
Adverse events · Reproductive and sexual health
Source sentences
Summary
There was no major adverse event.
1 context sentence(design, population, supporting numbers)
Summary · context
The treatment outcomes of 9 consecutive patients (study group) were compared with those of 51 patients (control group) who had been randomized (1:1) to receive HIFU (n = 24) or uterine artery embolization ([UAE] n = 27).
In this study, Oxytocin was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Oxytocin.
Report a problemFND-3149395601

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
11 Oct 2026, 01:30 UTC
Study results updated
Version 1
9 Oct 2026, 02:49 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.